/*! elementor – v3.6.5 – 27-04-2022 */
.elementor-heading-title{padding:0;margin:0;line-height:1}.elementor-widget-heading .elementor-heading-title[class*=elementor-size-]>a{color:inherit;font-size:inherit;line-height:inherit}.elementor-widget-heading .elementor-heading-title.elementor-size-small{font-size:15px}.elementor-widget-heading .elementor-heading-title.elementor-size-medium{font-size:19px}.elementor-widget-heading .elementor-heading-title.elementor-size-large{font-size:29px}.elementor-widget-heading .elementor-heading-title.elementor-size-xl{font-size:39px}.elementor-widget-heading .elementor-heading-title.elementor-size-xxl{font-size:59px}

Aims

This course aims to support primary care clinicians in:

• Recognising symptoms of ovarian cancer
• Understanding how genetic risk factors increase the likelihood of a cancer diagnosis
• Comprehending which investigations are essential to support clinical decisions when making a referral

Learning Objectives

This course aims to support primary care clinicians in:

• Recognising symptoms of ovarian cancer
• Understanding how genetic risk factors increase the likelihood of a cancer diagnosis
• Comprehending which investigations are essential to support clinical decisions when making a referral

Outline

The key elements of this course are:

• Facts and Figures
• Initial Presentation and Symptoms
• Differential Diagnoses
• Progression of Symptoms
• Primary Care Investigations
• Genomics
• NICE NG12 Guideline
• Link to GatewayC Live webinar
• Summary

There will be access to additional resources throughout the course.  These resources are optional should you want to deepen your knowledge of a particular aspect of the course. However, the time taken to access the resources is not included in the 1 hour time frame given to complete the course.

Contributors

This course was developed by The GatewayC Development Team, with digital and design support being provided by The Christie’s Digital Learning Team.

The following individuals were involved in the development of this course:

/*! elementor – v3.6.5 – 27-04-2022 */
.elementor-widget-image{text-align:center}.elementor-widget-image a{display:inline-block}.elementor-widget-image a img[src$=”.svg”]{width:48px}.elementor-widget-image img{vertical-align:middle;display:inline-block}

Prof. Gordon Jayson is a Professor of Medical Oncology at the University of Manchester, specialising in ovarian cancer and angiogenic drug development. He has led or written numerous phase I-III ovarian cancer trials, and has been developing a strategy for systemic therapy across Manchester.

/*! elementor – v3.6.5 – 27-04-2022 */
.e-container.e-container–row .elementor-spacer-inner{width:var(–spacer-size)}.e-container.e-container–column .elementor-spacer-inner,.elementor-column .elementor-spacer-inner{height:var(–spacer-size)}

Dr Emma Woodward is a Consultant Clinical Geneticist at Saint Mary’s Hospital, specialising in the inherited predisposition to adult and paediatric onset cancers. Dr Woodward has completed a PhD in familial pheochromocytoma and familial renal cancer, and completed her higher specialist training in Clinical Genetics in Birmingham.

This course is supported by Cancer Research UK, Ovarian Cancer Action, and Target Ovarian Cancer.

Copyright and Reviews

All content copyright is owned by The Christie NHS Foundation Trust, Wilmslow Road, Manchester, M20 4BX, United Kingdom

Date of publication: December 2020

Date of last review: December 2020

Endorsements

This course has been endorsed by the National Institute for Health and Care Excellence (NICE). To view our endorsement statement, please click here.